Pricing Log in Create free account

INmune Bio, Inc. (INMB) vs Pelthos Therapeutics Inc. (PTHS)

INmune Bio, Inc. and Pelthos Therapeutics Inc. are both Biotechnology companies. INmune Bio, Inc. and Pelthos Therapeutics Inc. are of similar size ($35.6M and $32.6M). INmune Bio, Inc. has the higher net margin (0.00% vs −199.5%) and the lower return on invested capital (−646.9% vs −82.3%). Across the 15 metrics below, INmune Bio, Inc. leads on 9 and Pelthos Therapeutics Inc. on 6.

Valuation

Metric INMB PTHS Biotechnology median
P/E n/m n/m 10.60
P/S 221.67 0.78 9.40
P/B 1.47 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 121.37 1.88 9.02
Earnings yield (59.82%) (276.23%) (32.88%)
Free cash flow yield (54.91%) (126.55%) (23.13%)

Profitability

Metric INMB PTHS Biotechnology median
Gross margin 100.00% 78.59% 68.51%
Operating margin 0.00% (133.42%) 0.00%
Net margin 0.00% (199.50%) 0.00%
Free cash flow margin 0.00% (98.37%) 0.00%
Return on equity (74.82%) 2,161.07% (51.96%)
Return on assets (57.08%) (125.04%) (46.06%)
Return on invested capital (646.94%) (82.34%) 0.00%

Growth

Metric INMB PTHS Biotechnology median
Revenue growth (TTM) (51.61%) — 6.76%
EPS growth (last fiscal year) 11.85% (61.12%) 29.88%
Revenue growth, 5-year CAGR 35.37% — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric INMB PTHS Biotechnology median
Debt to equity 0.00 (46.58) 0.00
Current ratio 4.04 1.98 4.97
Net debt to EBITDA 0.52 (0.45) 1.01

Dividend

Metric INMB PTHS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric INMB PTHS Biotechnology median
Market cap 32.61m 35.61m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack